Oseltamivir-resistant influenza A(H1N1)pdm2009 strains found in Brazil are endowed with permissive mutations, which compensate the loss of fitness imposed by antiviral resistance

Memorias do Instituto Oswaldo Cruz

Volumn 110, Issue 1, 2015, Pages 101-105

  Lopes E Souza, Thiago Moreno ^a,b   Fintelman Rodrigues, Natalia ^a   Resende, Paola Cristina ^a   Mesquita, Milene ^a   Gregianini, Tatiana Schaffer ^c   Bozza, Fernando A ^d   Pecego, Ana Carla ^d   Fernandes, Sandra Bianchini ^e   Furtado Cury, Ana Luisa ^f   Riediger, Irina Nastassja ^g   Siqueira, Marilda M ^a  

^a Laboratório de Vírus Respiratórios e do Sarampo   (Brazil)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

^c Fundacao Estadual de Producao e Pesquisa em Saude   (Brazil)

^d Funda??o Oswaldo Cruz   (Brazil)

^e Laboratório Central de Saúde Pública do Estado de Santa Catarina LACEN SC   (Brazil)

^f FUNDAÇÃO EZEQUIEL DIAS   (Brazil)

^g Laboratory of Bacteriology   (Brazil)

Author keywords

Antiviral; H275Y; Influenza A(H1N1)pdm09; Oseltamivir; Permissive mutation; Resistance

Indexed keywords

ANTIVIRUS AGENT; OSELTAMIVIR; SIALIDASE; VIRUS RNA;

ADULT; ANTIVIRAL RESISTANCE; BRAZIL; CLASSIFICATION; DRUG EFFECTS; FEMALE; GENETICS; HUMAN; INFLUENZA A VIRUS (H1N1); INFLUENZA, HUMAN; ISOLATION AND PURIFICATION; MUTATION; MUTATION RATE; NASAL LAVAGE FLUID; PHYLOGENY; PHYLOGEOGRAPHY; VIROLOGY;

ADULT; ANTIVIRAL AGENTS; BRAZIL; DRUG RESISTANCE, VIRAL; FEMALE; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; MUTATION; MUTATION RATE; NASAL LAVAGE FLUID; NEURAMINIDASE; OSELTAMIVIR; PHYLOGENY; PHYLOGEOGRAPHY; RNA, VIRAL;

EID: 84923130239     PISSN: 00740276     EISSN: 16788060     Source Type: Journal    
DOI: 10.1590/0074-02760140330     Document Type: Article

References (23)

1. Baillie GJ, Galiano M, Agapow PM, Myers R, Chiam R, Gall A, Palser AL, Watson SJ, Hedge J, Underwood A, Platt S, McLean E, Pebody RG, Rambaut A, Green J, Daniels R, Pybus OG, Kellam P, Zambon M 2012. Evolutionary dynamics of local pandemic H1N1/2009 influenza virus lineages revealed by whole-genome analysis. J Virol 86: 11-18.
2. Bloom JD, Nayak JS, Baltimore D 2011. A computational-experimental approach identifies mutations that enhance surface expression of an oseltamivir-resistant influenza neuraminidase. PLoS ONE 6: e22201.
3. Butler J, Hooper KA, Petrie S, Lee R, Maurer-Stroh S, Reh L, Guarnaccia T, Baas C, Xue L, Vitesnik S, Leang SK, McVernon J, Kelso A, Barr IG, McCaw JM, Bloom JD, Hurt AC 2014. Estimating the fitness advantage conferred by permissive neuraminidase mutations in recent oseltamivir-resistant A(H1N1)pdm09 influenza viruses. PLoS Pathog 10: e1004065.
4. CDC - Centers for Disease Control and Prevention 2013. Weekly U.S. Influenza Surveillance Report. FluView. A weekly influenza surveillance report prepared by the Influenza Division. 2013-2014 influenza season week 51 ending December 21, 2013. Available from: cdc.gov/flu/weekly/.
5. Correia V, Santos LA, Giria M, Almeida-Santos MM, Rebelo-de-Andrade H 2015. Influenza A(H1N1)pdm09 resistance and crossdecreased susceptibility to oseltamivir and zanamivir antiviral drugs. J Med Virol 87: 45-56.
6. Deyde VM, Sheu TG, Trujillo AA, Okomo-Adhiambo M, Garten R, Klimov AI, Gubareva LV 2010. Detection of molecular markers of drug resistance in 2009 pandemic influenza A (H1N1) viruses by pyrosequencing. Antimicrob Agents Chemother 54: 1102-1110.
7. Dixit R, Khandaker G, Ilgoutz S, Rashid H, Booy R 2013. Emergence of oseltamivir resistance: control and management of influenza before, during and after the pandemic. Infect Disord Drug Targets 13: 34-45.
8. Hurt AC, Ernest J, Deng YM, Iannello P, Besselaar TG, Birch C, Buchy P, Chittaganpitch M, Chiu SC, Dwyer D, Guigon A, Harrower B, Kei IP, Kok T, Lin C, McPhie K, Mohd A, Olveda R, Panayotou T, Rawlinson W, Scott L, Smith D, D’Souza H, Komadina N, Shaw R, Kelso A, Barr IG 2009. Emergence and spread of oseltamivirresistant A(H1N1) influenza viruses in Oceania, South East Asia and South Africa. Antiviral Res 83: 90-93.
9. Hurt AC, Hardie K, Wilson NJ, Deng YM, Osbourn M, Gehrig N, Kelso A 2011. Community transmission of oseltamivir-resistant A(H1N1)pdm09 influenza. N Engl J Med 365: 2541-2542.
10. Hurt AC, Hardie K, Wilson NJ, Deng YM, Osbourn M, Leang SK, Lee RT, Iannello P, Gehrig N, Shaw R, Wark P, Caldwell N, Givney RC, Xue L, Maurer-Stroh S, Dwyer DE, Wang B, Smith DW, Levy A, Booy R, Dixit R, Merritt T, Kelso A, Dalton C, Durrheim D, Barr IG 2012. Characteristics of a widespread community cluster of H275Y oseltamivir-resistant A(H1N1)pdm09 influenza in Australia. J Infect Dis 206: 148-157.
11. IBGE - Instituto Brasileiro de Geografia e Estatística 2010. Censo 2010. Available from: censo2010.ibge.gov.br.
12. Kelso A, Hurt AC 2012. The ongoing battle against influenza: drugresistant influenza viruses: why fitness matters. Nat Med 18: 1470-1471.
13. Lackenby A, Gilad JM, Pebody R, Miah S, Calatayud L, Bolotin S, Vipond I, Muir P, Guiver M, McMenamin J, Reynolds A, Moore C, Gunson R, Thompson C, Galiano M, Bermingham A, Ellis J, Zambon M 2011. Continued emergence and changing epidemiology of oseltamivir-resistant influenza A(H1N1)2009 virus, United Kingdom, winter 2010/11. Euro Surveill 16: 19784.
14. Meijer A, Lackenby A, Hay A, Zambon M 2007. Influenza antiviral susceptibility monitoring activities in relation to national antiviral stockpiles in Europe during the winter 2006/2007 season. Euro Surveill 12: E3-E4.
15. MS - Ministério da Saúde Brasil 2009. Protocolo de manejo clínico e vigilância epidemiológica da influenza, versão III, MS, Brasília, 32 pp.
16. Santesso N, Hsu J, Mustafa R, Brozek J, Chen YL, Hopkins JP, Cheung A, Hovhannisyan G, Ivanova L, Flottorp SA, Saeterdal I, Wong AD, Tian J, Uyeki TM, Akl EA, Alonso-Coello P, Smaill F, Schünemann HJ 2013. Antivirals for influenza: a summary of a systematic review and meta-analysis of observational studies. Influenza Other Respir Viruses 7 (Suppl. 2): 76-81.
17. Souza TM, Resende PC, Fintelman-Rodrigues N, Gregianini TS, Ikuta N, Fernandes SB, Cury AL, Rosa MC, Siqueira MM 2013. Detection of oseltamivir-resistant pandemic influenza A(H1N1) pdm2009 in Brazil: can community transmission be ruled out? PLoS ONE 8: e80081.
18. Storms AD, Gubareva LV, Su S, Wheeling JT, Okomo-Adhiambo M, Pan CY, Reisdorf E, George KS, Myers R, Wotton JT, Robinson S, Leader B, Thompson M, Shannon M, Klimov A, Fry AM 2012. Oseltamivir-resistant pandemic (H1N1) 2009 virus infections, United States, 2010-11. Emerg Infect Dis 18: 308-311.
19. Szretter KJ, Balish AL, Katz JM 2006. Influenza: propagation, quantification and storage. Curr Protoc Microbiol 3: C15-U15G.1.
20. Takashita E, Ejima M, Itoh R, Miura M, Ohnishi A, Nishimura H, Odagiri T, Tashiro M 2014. A community cluster of influenza A(H1N1)pdm09 virus exhibiting cross-resistance to oseltamivir and peramivir in Japan, November to December 2013. Euro Surveill 19: 20666.
21. WHO - World Health Organization 2009. CDC protocol of realtime RTPCR for influenza A(H1N1). Available from: who.int/csr/resources/ publications/swineflu/realtimeptpcr/en/.
22. WHO - World Health Organization 2011. WHO Global Influenza Network 2011. Manual for the laboratory diagnosis and virological surveillance of influenza, WHO, Geneva, 139 pp.
23. Zaraket H, Dapat C, Ghanem S, Ali Z, Lteif M, Kondo H, Dapat IC, Saito K, Kayali G, Suzuki H, Dbaibo G, Saito R 2014. Characterization of human influenza viruses in Lebanon during 2010-2011 and 2011-2012 post-pandemic seasons. Intervirology 57: 344-352.